Compact Pharmaceutical Manufacture Drug for Efferent Therapy - Enterosorbent ATC07

Transcript

1. Compact Pharmaceutical Manufacture Drug for Efferent Therapy Enterosorbent ATC07 BASOC laboratory Kyiv City, Ukraine basoclab@gmail.com Central Research Laboratory BASOC Development, Implementation and Production Drugs for Efferent Therapy
2. Recovery and maintenance of health requires elimination of toxins, pathogens and ballast substances from the body Intoxication determines the severity of the general human condition and makes ones feel ill Human intoxication occurs with diseases, poisoning, digestive disorders and many pathological processes A serious problem is the human intoxication following exogenous and endogenous poisoning
3. Mission – to provide affordable and effective drugs for the treatment of intoxication Key measures to treat intoxication is enterosorption Enterosorption - means binding and excretion of endogenous and exogenous substances, supramolecular structures and cells from the gastrointestinal tract Enterosorbents - drugs for excretion pathogens from the gastrointestinal tract for the treatment and prevention of diseases
4. 1 gram forms 300 sq.m. of strongly absorbing surface Broad-spectrum enterosorbent АТС07 is based on finely divided silica high selective sorption of protein toxins does not injure the mucous membrane of the gastrointestinal tract (GIT) allowed for all age categories no side effects remove the metabolic products and pathogens binds atherogenic cholesterol allows to halving the duration of treatment
5. Prevention and treatment atherosclerosis prevention diarrhea allergies alcohol intoxication intestinal infections, dysentery detoxification DETOX food poisoning
6. АТС07 Smecta Active-carbon allergies peptic ulcer after radiation therapy renal failure alcohol intoxication chronic hepatitis food poisoning diarrhea dysbacteriosis intestinal infections liver cirrhosis
7. Analogs Sales and Profitability Price Heilerde, Myrrhinil, Lefax Smecta Enterosgel, Polisorbum, Active-carbon € 10-15 $ 3 2 days $ 450 000 $ 4–8 $ 2–6 50% 1 year 2 M 25 g. 150 000 = = 300% АТС07 act. carbon АТС07 smecta
8. Description enterosorbent АТС07 Description light powder, white, tasteless, odorless Composition finely divided silica Pharmachologic effect enterosorption and detoxification Substance the powder is intended for preparing an oral suspension Pharmacodynamics absorbs protein toxins and pathogens in the lumen of the GIT Pharmacokinetics it is not absorbed in the GIT and excreted in the feces unchanged
9. Production АТС07 and raw materials Competitive advantages of production of the sorbent ATC07 low cost simple production cycle possibility of production and delivery small batches minimum storage costs of drugs minimum delivery time to consumers minimum shipping costs 3-5 pers. 380V/50Gz 700 kw Gegmany 3 м3 200 м2 150 000
10. Technology and documentation of the sorbent АТС07 production Quality Control Techniques Policy brief on enterosorbents use characteristics of raw materials, semi-finished products scheme of production space norms of the raw materials, semi-finished products and energy hardware scheme of production and equipment specification technology settings manuals industrial safety and environmental protection general scheme of a quality control system Production regulations description of production Technical specifications 1 2 3 4 Р1 Р2 Р3 Р4 Р5 Р7 Р8 Р9 Р6
11. Sorbents consumption in monetary terms Sorbents сonsumption in physical terms 60% silica-sorbent active-carbon $ 125 M 80% 87 million pack